報價延遲最少15分鐘:2024/05/17 07:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.62 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.65/-1.50
|
|
企業價值
613.74M
|
| 資產負債 |
|
每股賬面淨值
4.90
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/17 07:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases. |